메뉴 건너뛰기




Volumn 370, Issue 7, 2014, Pages 632-639

Genetic variants in C5 and poor response to eculizumab

(23)  Nishimura, Jun Ichi a   Yamamoto, Masaki a   Hayashi, Shin c   Ohyashiki, Kazuma d   Ando, Kiyoshi f   Brodsky, Andres L n   Noji, Hideyoshi g   Kitamura, Kunio h   Eto, Tetsuya i   Takahashi, Toru j   Masuko, Masayoshi k   Matsumoto, Takuro l   Wano, Yuji m   Shichishima, Tsutomu g   Shibayama, Hirohiko a   Hase, Masakazu e   Li, Lan o   Johnson, Krista o   Lazarowski, Alberto n   Tamburini, Paul o   more..


Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; ECULIZUMAB; GENOMIC DNA; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY N19 8; UNCLASSIFIED DRUG;

EID: 84893799889     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1311084     Document Type: Article
Times cited : (297)

References (25)
  • 2
    • 0027310539 scopus 로고
    • Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria
    • DOI 10.1016/0092-8674(93)90250-T
    • Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11. (Pubitemid 23159009)
    • (1993) Cell , vol.73 , Issue.4 , pp. 703-711
    • Takeda, J.1    Miyata, T.2    Kawagoe, K.3    Iida, Y.4    Endo, Y.5    Fujita, T.6    Takahashi, M.7    Kitani, T.8    Kinoshita, T.9
  • 5
    • 69249221393 scopus 로고    scopus 로고
    • How I treat paroxysmal nocturnal hemoglobinuria
    • Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009;113:6522-7.
    • (2009) Blood , vol.113 , pp. 6522-6527
    • Brodsky, R.A.1
  • 6
    • 79957546158 scopus 로고    scopus 로고
    • Management of paroxysmal nocturnal haemoglobinuria: A personal view
    • Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 2011;153:709-20.
    • (2011) Br J Haematol , vol.153 , pp. 709-720
    • Luzzatto, L.1    Gianfaldoni, G.2    Notaro, R.3
  • 10
    • 35948959015 scopus 로고    scopus 로고
    • Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    • DOI 10.1038/nbt1344, PII NBT1344
    • Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64. [Erratum, Nat Biotechnol 2007;25:1488.] (Pubitemid 350076509)
    • (2007) Nature Biotechnology , vol.25 , Issue.11 , pp. 1256-1264
    • Rother, R.P.1    Rollins, S.A.2    Mojcik, C.F.3    Brodsky, R.A.4    Bell, L.5
  • 11
    • 60649118722 scopus 로고    scopus 로고
    • Eculizumab for paroxysmal nocturnal haemoglobinuria
    • Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373:759-67.
    • (2009) Lancet , vol.373 , pp. 759-767
    • Parker, C.1
  • 13
  • 17
    • 78751581550 scopus 로고    scopus 로고
    • Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS clinical trial
    • Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 2011;93:36-46.
    • (2011) Int J Hematol , vol.93 , pp. 36-46
    • Kanakura, Y.1    Ohyashiki, K.2    Shichishima, T.3
  • 18
    • 65449188713 scopus 로고    scopus 로고
    • Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
    • Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094-100.
    • (2009) Blood , vol.113 , pp. 4094-4100
    • Risitano, A.M.1    Notaro, R.2    Marando, L.3
  • 19
    • 0025936774 scopus 로고
    • Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
    • Würzner R, Schulze M, Happe L, et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991;8:328-40.
    • (1991) Complement Inflamm , vol.8 , pp. 328-340
    • Würzner, R.1    Schulze, M.2    Happe, L.3
  • 20
    • 0033661188 scopus 로고    scopus 로고
    • Purification of complement components, regulators, and receptors by classical methods
    • van den Berg CW. Purification of complement components, regulators, and receptors by classical methods. Methods Mol Biol 2000;150:15-52.
    • (2000) Methods Mol Biol , vol.150 , pp. 15-52
    • Van Den Berg, C.W.1
  • 24
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammarIIIa gene
    • DOI 10.1182/blood.V99.3.754
    • Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
    • (2002) Blood , vol.99 , Issue.3 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3    Solal-Celigny, P.4    Bardos, P.5    Colombat, P.6    Watier, H.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.